Fig. 2From: One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry studyReponder rates (≥ 30%, ≥ 50% as primary endopoint, ≥ 75%) et M3, M6, M9 and M12Back to article page